The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
ABPI open letter to the Conservative candidates for Prime Minister
The ABPI calls on the Conservative candidates to prevent the UK slipping behind our global competitors in the race to become a life sciences superpower and to deliver on the ambition set out in the Conservative Party Manifesto and the Life Sciences Vision.
Read the ABPI Open Letter to the Conservative CandidatesLatest news
Open letter to Secretary of State for International Trade on UK-India negotiations
The ABPI is one of 11 major cross-sector business groups that have written to Anne-Marie Trevelyan on talks between the UK and India
ABPI statement on biomarker testing
The ABPI commented in support of a call led by the Institute of Cancer Research (ICR) for all cancer patients to be offered genetic testing so they can get the best treatments available for them.
ABPI response to Life Sciences Competitiveness Indicators
The Government has today published Life Sciences Competitiveness Indicators, which provide data on the state of the life sciences sector in the UK.
ABPI welcomes first women's health strategy for England
The Government has today published the first women's health strategy for England, to tackle the gender health gap.
Latest blogs and events
The Innovative Medicines Fund - Good news for patients but has an opportunity been missed to be more ambitious?
NHS England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund. The ABPI’s Director of Value and Access Policy, Paul Catchpole, provides further commentary on the announcement.
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
Key content hubs
This covers the latest research from the ABPI-Ipsos attitudes towards pharmaceutical companies in the UK study.
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Our Director of Partnerships Colette Goldrick was in Birmingham yesterday to discuss life sciences innovation and see some brilliant sporting action. Thanks for hosting @uob_be @DrBruceKeogh @Jpisani #CommonwealthGames2022 #GameChangingBusiness 🔬🧬🖥️🏆 pic.twitter.com/v64M4iQ3ba
— ABPI (@ABPI_UK) August 9, 2022
We support this call - read our full response here https://t.co/H6tzdN0mdO https://t.co/BfVSjb8C8d
— ABPI (@ABPI_UK) August 8, 2022
Biomarker testing can change lives - see today's @thetimes
— ABPI (@ABPI_UK) August 8, 2022
We are part of the coalition calling for more tests like this https://t.co/Vh2aSKkEu8
Interesting report from @UKOnward today on how to make the UK a #ScienceSuperpower. The pharmaceutical industry invests more in UK R&D than any other sector and is critical to success. 🔽 https://t.co/Cwe6SFFacl
— ABPI (@ABPI_UK) August 4, 2022
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [3]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.